Stockscreener 앱 받기
27.72
2.82%
0.76
시간 외 거래:
27.17
-0.55
-1.98%
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
TVTX SEC FilingsTravere Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $280,900.00 in Stock - MarketBeat
Travere Therapeutics (TVTX) CLO exercises options and sells 10K shares - Stock Titan
Travere Therapeutics (TVTX) reports 144% annual growth in Filspari sales for 2025 - MSN
Travere Therapeutics, Inc. (TVTX) positioned for long-term growth in rare disease market - MSN
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Cinctive Capital Management LP Makes New $2.26 Million Investment in Travere Therapeutics, Inc. $TVTX - MarketBeat
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
166,000 Shares in Travere Therapeutics, Inc. $TVTX Purchased by Apis Capital Advisors LLC - MarketBeat
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall - Sahm
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts - MSN
Understanding the Setup: (TVTX) and Scalable Risk - Stock Traders Daily
How liquid is Travere Therapeutics Inc. stockProfit Target & Smart Investment Allocation Insights - mfd.ru
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) - Finviz
Assessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment - Sahm
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Kentucky Teachers Retirement System Invests $732,000 in Travere Therapeutics - National Today
Travere Therapeutics, Inc. $TVTX Shares Sold by GW&K Investment Management LLC - MarketBeat
Published on: 2026-03-07 06:27:27 - baoquankhu1.vn
Royce & Associates Reduces Stake in Travere Therapeutics - National Today
Royce & Associates LP Reduces Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Vanguard Group Inc. Has $158.06 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Exploring a 44.65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Legato Capital Management LLC Acquires Shares of 71,030 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
TVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Total debt per share of Travere Therapeutics, Inc. – BOATS:TVTX - TradingView
Travere Therapeutics (TVTX) Is Up 7.4% After FILSPARI-Fueled Revenue Surge And Narrower LossesHas The Bull Case Changed? - simplywall.st
Travere Therapeutics, Inc. (TVTX) Stock Analysis: A 39% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Travere Therapeutics (TVTX) CEO sells 60,000 shares in 10b5-1 trade - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory - Finviz
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 - Finviz
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX) - Seeking Alpha
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Accendra Health (ACH) and Travere Therapeutics (TVTX) - The Globe and Mail
Assessing Travere Therapeutics (TVTX) Valuation After Strong Earnings Beat And Pipeline Progress - Sahm
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to Buy - MarketBeat
Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (IART) and Travere Therapeutics (TVTX) - The Globe and Mail
Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins - MSN
Travere Therapeutics Earnings Call Shows Growth Amid Risks - TipRanks
TVTX (NASDAQ): Affiliate files Form 144 to sell 60,000 shares - Stock Titan
Travere Therapeutics (NASDAQ:TVTX) Shares Down 5.4%Should You Sell? - MarketBeat
Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights - GuruFocus
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics Q4 Earnings Call Highlights - MarketBeat
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
1.20%
0.06%
자본화:
|
볼륨(24시간):